- Home
- LXRX vs CLLS Comparison
LXRX vs CLLS Comparison
Compare LXRX & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- CLLS
- Stock Information
- Founded
- LXRX 1995
- CLLS 1999
- Country
- LXRX United States
- CLLS France
- Employees
- LXRX N/A
- CLLS N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- LXRX Health Care
- CLLS Health Care
- Exchange
- LXRX Nasdaq
- CLLS Nasdaq
- Market Cap
- LXRX 124.4M
- CLLS 148.1M
- IPO Year
- LXRX 2000
- CLLS 2007
- Fundamental
- Price
- LXRX $0.46
- CLLS $1.32
- Analyst Decision
- LXRX Buy
- CLLS Buy
- Analyst Count
- LXRX 4
- CLLS 3
- Target Price
- LXRX $3.67
- CLLS $7.00
- AVG Volume (30 Days)
- LXRX 30.7M
- CLLS 839.3K
- Earning Date
- LXRX 03-06-2025
- CLLS 03-13-2025
- Dividend Yield
- LXRX N/A
- CLLS N/A
- EPS Growth
- LXRX N/A
- CLLS N/A
- EPS
- LXRX N/A
- CLLS N/A
- Revenue
- LXRX $31,081,000.00
- CLLS $49,217,000.00
- Revenue This Year
- LXRX N/A
- CLLS $1.26
- Revenue Next Year
- LXRX $101.91
- CLLS N/A
- P/E Ratio
- LXRX N/A
- CLLS N/A
- Revenue Growth
- LXRX 2481.48
- CLLS 435.38
- 52 Week Low
- LXRX $0.28
- CLLS $1.14
- 52 Week High
- LXRX $2.45
- CLLS $3.38
- Technical
- Relative Strength Index (RSI)
- LXRX 50.39
- CLLS 49.18
- Support Level
- LXRX $0.32
- CLLS $1.16
- Resistance Level
- LXRX $0.71
- CLLS $1.35
- Average True Range (ATR)
- LXRX 0.06
- CLLS 0.07
- MACD
- LXRX 0.03
- CLLS 0.01
- Stochastic Oscillator
- LXRX 36.95
- CLLS 69.23
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.